We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05502393
Recruitment Status : Recruiting
First Posted : August 16, 2022
Last Update Posted : August 16, 2022
Information provided by (Responsible Party):
Shanghai Junshi Bioscience Co., Ltd.

Brief Summary:
The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS107 monotherapy and combination with Toripalimab in patients with Advanced or Metastatic Solid Tumors.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: JS107 Drug: Toripalimab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 118 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Intervention Model Description: Sequential
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics of JS107 in Patients With Advanced Solid Tumors
Actual Study Start Date : July 26, 2022
Estimated Primary Completion Date : July 31, 2024
Estimated Study Completion Date : December 31, 2024

Arm Intervention/treatment
Experimental: JS107 Drug: JS107
JS107, i.v., q3w

Experimental: JS107 combination with Toripalimab Drug: JS107
JS107, i.v., q3w

Drug: Toripalimab
Toripalimab i.v., q3w

Primary Outcome Measures :
  1. MTD [ Time Frame: Up to approximately 12 months from first patient in. ]
    Determine maximum tolerated dose (MTD, if possible)

  2. RP2D [ Time Frame: Up to approximately 24 months from first patient in. ]
    Recommended phase II dose (RP2D) for JS107 monotherapy and combination therapy

Secondary Outcome Measures :
  1. Drug concentrations [ Time Frame: Up to approximately 24 months from first patient in. ]
    Drug concentrations in individual subjects at different time points after dosing

  2. Immunogenicity [ Time Frame: Up to approximately 24 months from first patient in. ]
    Incidence of anti-drug antibody (ADA) and/or neutralizing antibody (Nab), titer of ADA positive samples

  3. ORR [ Time Frame: Up to approximately 24 months from first patient in. ]
    Objective response rate (ORR) was assessed based on RECIST V1.1 criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. The subjects voluntarily participated in the study with full informed consent and signed written informed consent form;
  2. Aged ≥18 years and ≤75 years when the subject signed the informed consent;
  3. Locally advanced unresectable or metastatic malignant solid tumors diagnosed histologically ;
  4. Provide past tumor samples or fresh tumor tissue biopsy samples;
  5. The physical status score is 0 or 1 on the Eastern Oncology Collaboration (ECOG) scale;
  6. The expected survival is ≥3 months;
  7. There should be at least one measurable lesion according to RECIST V1.1 evaluation criteria;
  8. Any adverse events and/or complications resulting from prior treatment, including surgery or radiation therapy, that have been adequately resolved to level 0 or 1 (according to the NATIONAL Cancer Institute Standard for General Terminology of Adverse Events (NCI-CTCAE 5.0) or to the level specified in the inclusion criteria; Any grade of hair loss/pigmentation and other long-term toxicity caused by treatment, except those that are irreversible and do not affect study dosing/compliance and patient safety at the discretion of the investigator;
  9. Good organ function;
  10. Within 7 days prior to the first dose, women of reproductive age must be confirmed as having a negative serum pregnancy test and consent to use effective contraception during the duration of study drug use and for 6 months after the last dose. Male patients with a female partner of reproductive age agreed to use effective contraception during the study drug use period and for 6 months after the last dose.

Exclusion Criteria:

  1. Prior treatment with drugs or other therapies targeting CLDN18.2;
  2. A history of severe allergic reactions to other monoclonal antibodies or to any component of JS107, or to other drugs or excipients involved in the trial protocol ;
  3. Received radiotherapy (except palliative radiotherapy for symptom control), chemotherapy, targeted therapy, endocrine therapy and other antitumor therapies, or other investigational drugs within 4 weeks before the administration of the first dose;
  4. Received any monoclonal antibody or antibody conjugate within 4 weeks prior to administration of the first study drug or within 5 half-lives (depend on whichever is shorter);
  5. Persons who have an immunodeficient disease or the other chronic immunosuppressive therapy, or who have received systemic immunomodulatory drugs (including, but not limited to, interferon or IL-2) within 14 days before first dose or within the 5 half-life of the drug (depend on whichever is longer), or received systemic glucocorticoid therapy (10mg daily of prednisone or equivalent glucocorticoids) or other systemic immunosuppressive therapy within 14 days before first dose;
  6. Received any live vaccine (e.g. influenza vaccine against infectious diseases, chickenpox vaccine, etc.) within 14 days before first dose;
  7. Serious infection (CTCAE> grade 2) occurred within 14 days before the first dose;
  8. Patients with other malignant tumors except for the tumor treated in the study within 5 years prior to the administration of the first study drug (exceptions included: cured malignancies that had not recurred within 3 years prior to study enrollment; Completely resected basal and squamous cell skin cancers; Complete resection of any type of carcinoma in situ, etc.);
  9. Major organ surgery was performed or significant trauma was present within 4 weeks before the first administration of the study drug;
  10. Weight loss 10% within 2 months before drug administration, or other indicators of severe malnutrition, or body mass index (BMI)<17.5 at the time of signing the informed consent.
  11. The following conditions were present within 6 months prior to the first study dose: myocardial infarction, severe/unstable angina, NYHA class 2 or higher cardiac insufficiency, clinically significant supraventricular or ventricular arrhythmia, and symptomatic congestive heart failure , hypertensive crisis, or hypertensive encephalopathy; patients with known hypertension, coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction <50% must be treated with optimal stabilization as determined by the treating physician medical plan;
  12. Pericardial effusion, pleural effusion or abdominal effusion with clinical symptoms, signs or requiring symptomatic treatment;
  13. Poorly controlled pain related;
  14. The presence of uncontrolled or symptomatic active central nervous system (CNS) metastases, which can be manifested by the onset of clinical symptoms, cerebral edema, spinal cord compression, carcinomatous meningitis, leptomeningeal disease, and/or progressive growth;
  15. Active infection, including tuberculosis (clinical diagnosis including clinical history, physical examination and imaging findings, as well as TB tests according to local medical routine), hepatitis B, hepatitis C or human immunodeficiency virus (HIV antibody positive);
  16. History of autoimmune disease;
  17. Idiopathic pulmonary fibrosis, drug-induced pneumonia, machine-induced pneumonia (bronchiolitis obliterans), radioactive pneumonia with clinical symptoms or requiring steroid treatment, active pneumonia, or other moderate to severe lung diseases that seriously affect lung function ;
  18. Pregnant or lactating women;
  19. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
  20. Have serious psychological or mental abnormality, which affects the compliance of the subject to participate in this clinical study;
  21. Participated in any other clinical trial within 28 days prior to the first administration of study drug;
  22. Other conditions deemed inappropriate for study participation by the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05502393

Layout table for location contacts
Contact: Ruihua Xu, M.D 86 020-87342479 xurh@sysucc.org.cn
Contact: Furong Liu, Medicie Postgraduate 86 020-87342479 liufr@sysucc.org.cn

Layout table for location information
China, Fujian
Fujian Cancer Hospital Not yet recruiting
Fuzhou, Fujian, China, 350014
Contact: Rongbo Lin, M.D.    86 0591-83660063    Rongbo_lin@163.com   
Principal Investigator: Rongbo Lin, M.D.         
China, Guangdong
Sun Yat-sen University Cancer Center Recruiting
Guangzhou, Guangdong, China, 510060
Contact: Ruihua Xu, M.D.    86 020-87342479    xurh@sysucc.org.cn   
Principal Investigator: Ruihua Xu, Study Principal Investigator         
China, Zhejiang
The First Affiliated Hospital of Zhejiang University Medical College Not yet recruiting
Hangzhou, Zhejiang, China, 310003
Contact: Jianzhen Shan, M.D.    86 0571-87236114    jianzhenshan@163.com   
Principal Investigator: Jianzhen Shan, M.D.         
Sponsors and Collaborators
Shanghai Junshi Bioscience Co., Ltd.
Layout table for investigator information
Principal Investigator: Ruihua Xu, M.D. Sun Yat-sen University
Layout table for additonal information
Responsible Party: Shanghai Junshi Bioscience Co., Ltd.
ClinicalTrials.gov Identifier: NCT05502393    
Other Study ID Numbers: JS107-001-I
First Posted: August 16, 2022    Key Record Dates
Last Update Posted: August 16, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms